Vandetanib

(Caprelsa®)

Vandetanib

Drug updated on 11/8/2023

Dosage FormTablet (oral; 100 mg, 300 mg)
Drug ClassKinase inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.

Product Monograph / Prescribing Information

Document TitleYearSource
Caprelsa (vandetanib) Prescribing Information.2022Sanofi Genzyme Cambridge, MA

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines